A meta‐analysis of 119 trials including 64 768 participants with CKD reported that the use of angiotensin‐converting enzyme inhibitors or angiotensin‐receptor blockers, when compared with placebo, reduced kidney failure (odds ratio [OR], 0.61; 95% credible interval, 0.47–0.79 and OR, 0.70; 95% credible interval, 0.52–0.89, respectively) and reduced major CV events (OR, 0.82; 95% credible interval, 0.71–0.92 and OR, 0.76; 95% credible interval, 0.62–0.89, respectively) (Table 1).78 This evidence concerns the gene ACE and chronic kidney disease.